Physician profile
Steven Thomas O'Donnell
NPI 1922057363
$3,363.39
in general payments reported to CMS, 2019-2025
22 companies · $871 in 2025
The $871 reported for 2025 was more than what 84% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $188 · 2021: $560 · 2022: $483 · 2023: $624 · 2024: $451 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.12 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,210.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $355.18 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $309.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $286.60 | 2020-2025 | Proclaim, Freestyle Libre 3 |
| Amgen INC. | $227.58 | 2024-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $145.59 | 2019-2023 | Steglatro, Belsomra |
| Pfizer INC. | $132.24 | 2020-2025 | |
| Philips North America LLC | $131.09 | 2021-2025 | Vest Therapy Und |
| Exact Sciences Corporation | $122.29 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $97.67 | 2021-2023 | Injectafer |
| Tonix Medicines, INC. | $76.22 | 2025 | Tonmya |
| Abbvie INC. | $62.45 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $45.21 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $36.41 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $28.73 | 2025 | Ultomiris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.96 | 2019 | |
| Hikma Pharmaceuticals USA | $16.03 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.03 | 2021 | |
| Medtronic, INC. | $15.91 | 2023 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $15.57 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.36 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven O'Donnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.